RxDoctor Payments Data

William King, MD

Internal Medicine · Eufaula, ALNPI 1891715892

Payments from drug & device makers

$1,681in general payments, 2019–2025

Across 112 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$549
  • Pfizer$267
  • Lilly USA, LLC$191
  • AstraZeneca$134
  • Merck$94
  • Amarin Pharma, Inc.$83
  • plus $363 from 10 others

What the payments were for

  • Food & beverage$1,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,681 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$114,579
Medicare patients
251
Services billed
1,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate208$215,533
EliquisApixaban238$189,202
MounjaroTirzepatide88$124,603
JardianceEmpagliflozin109$123,621
OzempicSemaglutide72$101,133
FarxigaDapagliflozin Propanediol97$81,181
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$79,825
TrulicityDulaglutide46$79,781
EntrestoSacubitril/Valsartan50$38,859
XareltoRivaroxaban31$29,339
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$27,685
Breo ElliptaFluticasone/Vilanterol32$23,175
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$20,144
Spiriva RespimatTiotropium Bromide22$19,789
TradjentaLinagliptin19$15,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Belsomra$94$221,659220 claims
Lilly USA, LLCMounjaro, Trulicity$191$204,383134 claims
PfizerEliquis$267$189,202238 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Glyxambi$33$171,457163 claims
AstraZenecaFarxiga, Breztri Aerosphere$134$108,866131 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$25$107,200118 claims
Novo NordiskOzempic$549$101,13372 claims
NovartisEntresto$80$38,85950 claims
Johnson & JohnsonXarelto$38$29,33931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Eufaula

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →